Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TMDX
stocks logo

TMDX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
156.34M
+28.54%
0.396
+108.27%
170.61M
+18.86%
0.760
+8.57%
184.70M
+17.37%
0.850
-7.61%
Estimates Revision
The market is revising Upward the revenue expectations for TransMedics Group, Inc. (TMDX) for FY2025, with the revenue forecasts being adjusted by 0.56% over the past three months. During the same period, the stock price has changed by 33.29%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.56%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+14.08%
In Past 3 Month
Stock Price
Go Up
up Image
+33.29%
In Past 3 Month
Wall Street analysts forecast TMDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMDX is 143.67 USD with a low forecast of 115.00 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast TMDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMDX is 143.67 USD with a low forecast of 115.00 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 138.630
sliders
Low
115.00
Averages
143.67
High
170.00
Current: 138.630
sliders
Low
115.00
Averages
143.67
High
170.00
Morgan Stanley
Equal Weight
maintain
$123 -> $135
2025-12-02
New
Reason
Morgan Stanley
Price Target
$123 -> $135
2025-12-02
New
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on TransMedics to $135 from $123 and keeps an Equal Weight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.
Canaccord
Buy
maintain
$142 -> $147
2025-10-30
Reason
Canaccord
Price Target
$142 -> $147
2025-10-30
maintain
Buy
Reason
Canaccord raised the firm's price target on TransMedics to $147 from $142 and keeps a Buy rating on the shares. The firm said they delivered revenue in line with the firm's estimates, but slightly short of consensus which may present an interesting buying opportunity. Given the expectation for a seasonally slow and relatively in-line quarter, they believe their thesis is intact and believe any dip in the stock price creates a buying opportunity for longer-term investors,
Piper Sandler
Matt O'Brien
Overweight
downgrade
$145 -> $140
2025-10-30
Reason
Piper Sandler
Matt O'Brien
Price Target
$145 -> $140
2025-10-30
downgrade
Overweight
Reason
Piper Sandler analyst Matt O'Brien lowered the firm's price target on TransMedics to $140 from $145 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results that landed just shy of consensus on the top line but handily beat on the bottom-line. Despite the revenue performance, management raised the midpoint of its full-year sales guidance based on business momentum and the nice Q4 start seen in October. Piper thinks the FY25 sales and OM outlook is conservative and should deliver upside to end the year.
Needham
Hold
to
Buy
upgrade
$148
2025-10-23
Reason
Needham
Price Target
$148
2025-10-23
upgrade
Hold
to
Buy
Reason
Needham upgraded TransMedics to Buy from Hold with a $148 price target. Needham's transplant tracker indicates that TransMedics' U.S. sales are likely to beat consensus in Q3, the analyst tells investors in a research note. The firm also expects the company's new heart and lung clinical trials and its international expansion to become growth drivers in 2026. Meanwhile, TransMedics' margins are "increasing rapidly," which should drive upside to earnings estimates, contends the analyst. Needham thinks the company "has a significant lead in a still significantly underpenetrated market."
Evercore ISI
Outperform
initiated
$155
2025-09-16
Reason
Evercore ISI
Price Target
$155
2025-09-16
initiated
Outperform
Reason
Evercore ISI initiated coverage of TransMedics with an Outperform rating and $155 price target. There is a misunderstanding among investors that the cost of TransMedics' services are materially higher than competitive alternatives, but the firm's analysis shows total costs are similar, despite materially better patient outcomes, the analyst tells investors. The firm cites the company's "differentiated" end-to-end organ transplant offering and "impressive financial outlook" for its Outperform rating on TransMedics.
Stifel
Hold
initiated
$115
2025-09-03
Reason
Stifel
Price Target
$115
2025-09-03
initiated
Hold
Reason
Stifel initiated coverage of TransMedics with a Hold rating and $115 price target. The firm would characterize results of its survey of 19 U.S. transplant surgeons survey as "mixed," reporting surgeon feedback suggests TransMedics' OCS portable organ perfusion, optimization, and monitoring system may face market share pressure, driven by competition. When factoring in the mixed survey findings, the firm believe risk-reward is balanced at current levels against its "confidence in meaningful upside potential to estimates," the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Transmedics Group Inc (TMDX.O) is 53.92, compared to its 5-year average forward P/E of -9.12. For a more detailed relative valuation and DCF analysis to assess Transmedics Group Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.12
Current PE
53.92
Overvalued PE
78.52
Undervalued PE
-96.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.99
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
90.36
Undervalued EV/EBITDA
-100.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.71
Current PS
0.00
Overvalued PS
16.81
Undervalued PS
4.60
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TMDX News & Events

Events Timeline

(ET)
2025-11-19
12:02:50
TransMedics Shares Increase by 10.4%
select
2025-09-26 (ET)
2025-09-26
16:09:41
TransMedics and Mercedes-Benz Collaborate on Organ Transport Services in Italy
select
2025-09-22 (ET)
2025-09-22
05:14:09
TransMedics Partners with Mercedes-Benz Group for Organ Transport Services in Italy
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.0
11-26CNBC
This organ transport stock is surging. Here's what the charts suggest about its potential trajectory.

  • Health Care Sector Performance: The health care sector has been underperforming the broader market since 2023, but signs indicate a potential breakout, particularly if the XLV index closes above $158, which would confirm a significant upward trend.

  • Factors Driving Health Care Growth: Three key reasons for the sector's resurgence include a rotation into defensive sectors, improving fundamentals with the rise of GLP-1 and obesity drugs, and advancements in AI that enhance drug discovery and clinical trials.

  • Telemedics (TMDX) Overview: TMDX is gaining attention for its innovative organ care system that improves organ transport, and while not officially an AI company, it is building a substantial database that could support future AI applications in organ donation logistics.

  • Investment Strategy: Inside Edge Capital has added a 2% position in TMDX, with plans to increase the allocation by 50% if the stock breaks above $145, reflecting confidence in the company's strong revenue growth and market potential.

[object Object]
Preview
6.5
11-25NASDAQ.COM
1 Growth Stock I'm Grateful For – and the Irresistible Stock I'm Investing In Based on Its Insights

  • Investment Lessons from Amazon: The author reflects on their experience as an Amazon shareholder, emphasizing the importance of avoiding short-term thinking and trusting founder-led companies, even when faced with setbacks like the Fire Phone failure.

  • TransMedics Group Investment: The author discusses their investment in TransMedics Group, which provides innovative organ care systems, and how they chose to hold onto the stock despite initial concerns over a capital-intensive acquisition.

  • Growth and Future Potential: TransMedics has seen significant growth, with its stock tripling from lows and sales doubling, as the company aims to expand its transplant operations and enter new markets.

  • Learning from Mistakes: The author shares a humorous quote from Warren Buffett about learning from mistakes, highlighting the value of patience and allowing management to execute their long-term vision in the context of investing.

[object Object]
Preview
2.0
11-20CNBC
Midday Stock Highlights: Significant Movements from Alphabet, Nvidia, Lowe's, La-Z-Boy, MP Materials, and Others

  • Alphabet's Success: Alphabet's stock rose 4% to an all-time high following the launch of its Gemini 3 AI platform, which enhances user interaction by providing better answers with less prompting.

  • Eversource's Setback: Eversource's shares fell over 8% after Connecticut rejected its sale of the Aquarion Water unit, impacting investor confidence.

  • Dycom Industries' Strong Performance: Dycom Industries saw a 9% increase in shares after exceeding earnings expectations, driven by demand from AI data centers, and reported a record backlog of $8.2 billion.

  • Mixed Results for Other Companies: La-Z-Boy and Viking reported strong earnings, leading to stock increases, while Plug Power's shares dropped 12% due to plans for a $375 million convertible notes offering.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Transmedics Group Inc (TMDX) stock price today?

The current price of TMDX is 138.63 USD — it has decreased -1.05 % in the last trading day.

arrow icon

What is Transmedics Group Inc (TMDX)'s business?

TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

arrow icon

What is the price predicton of TMDX Stock?

Wall Street analysts forecast TMDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMDX is 143.67 USD with a low forecast of 115.00 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Transmedics Group Inc (TMDX)'s revenue for the last quarter?

Transmedics Group Inc revenue for the last quarter amounts to 143.82M USD, increased 32.24 % YoY.

arrow icon

What is Transmedics Group Inc (TMDX)'s earnings per share (EPS) for the last quarter?

Transmedics Group Inc. EPS for the last quarter amounts to 0.60 USD, increased 400.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Transmedics Group Inc (TMDX)'s fundamentals?

The market is revising Upward the revenue expectations for TransMedics Group, Inc. (TMDX) for FY2025, with the revenue forecasts being adjusted by 0.56% over the past three months. During the same period, the stock price has changed by 33.29%.
arrow icon

How many employees does Transmedics Group Inc (TMDX). have?

Transmedics Group Inc (TMDX) has 728 emplpoyees as of December 05 2025.

arrow icon

What is Transmedics Group Inc (TMDX) market cap?

Today TMDX has the market capitalization of 4.74B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free